Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy
American Journal of Cancer Research · 2024 · 14 (3) · 1033-1051
DOI: 10.62347/eynt8387 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cancer Research, 2024. Verfasst von Shinichiro Kina und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education and Development, Graduate School of Medicine, Gunma University Maebashi, Gunma, Japan. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Distant metastasis is an important prognostic factor for oral squamous cell carcinoma (OSCC). It involves the direct spread of tumor cells through blood vessels or via lymph nodes; however, there are currently no well-established treatments for its prevention in patients with OSCC. To investigate the impact of metronomic neoadjuvant chemotherapy on OSCC, we conducted a retrospective analysis of the efficacy of neoadjuvant chemotherapy with S-1 alone. Fifty-four patients underwent up-front surgery, while 106 received neoadjuvant chemotherapy with S-1 alone. A serious adverse event occurred in one of patient treated with neoadjuvant chemotherapy (1%); however, all patients underwent resection. The 5-year overall survival rate was higher with S-1 than with up-front surgery (96% vs. 81%, P = 0.002). Moreover, neoadjuvant chemotherapy significantly increased the overall survival rate of patients with poorly or moderately differentiated tumors, but not those with well-differentiated tumors. By analyzing a cohort of 523 head and neck squamous cell carcinoma (HNSCC) patients in the Cancer Genome Atlas, we identified genetic variants associated with histological differentiation. The frequency of pathogenic/likely pathogenic variants or deletions in 5 genes associated with HNSCC correlated with histological differentiation, some of which indicated the activation of the Wnt/β-catenin pathway in well-differentiated HNSCC. The vessel marker CD31 was highly expressed in poorly differentiated OSCC, whereas the anti-angiogenic molecule, LCN2, which is induced by the activation of the Wnt pathway, was highly expressed in well-differentiated OSCC. The present study showed that overall survival rates were higher in patients with poorly or moderately differentiated OSCC who received metronomic neoadjuvant chemotherapy, which was attributed to a difference in angiogenesis based on the characteristic landscape of pathogenic mutations according to histological differentiation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Education and Development, Graduate School of Medicine, Gunma University Maebashi, Gunma, Japan.
- Department of Oral Surgery, Sapporo Medical University School of Medicine South-1, West-16, Chuo-ku, Sapporo, Hokkaido, Japan.
- Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research, Gunma University Maebashi, Gunma, Japan.
- Department of Oral and Maxillofacial Surgery and Plastic Surgery, Graduate School of Medicine, Gunma University Maebashi, Gunma, Japan.
Zitieren
APA
Kina, S., Miyamoto, S., Kawabata-Iwakawa, R., Kina-Tanada, M., Ogawa, M., & Yokoo, S. (2024). Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy. American Journal of Cancer Research, 14(3), 1033-1051. https://doi.org/10.62347/eynt8387
Vancouver
Kina S, Miyamoto S, Kawabata-Iwakawa R, Kina-Tanada M, Ogawa M, Yokoo S. Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy. American Journal of Cancer Research. 2024;14(3):1033-1051. doi:10.62347/eynt8387
BibTeX
@article{Kina2024,
author = {Kina, Shinichiro and Miyamoto, Sho and Kawabata-Iwakawa, Reika and Kina-Tanada, Mika and Ogawa, Masaru and Yokoo, Satoshi},
title = {Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy},
journal = {American Journal of Cancer Research},
year = {2024},
volume = {14},
number = {3},
pages = {1033--1051},
doi = {10.62347/eynt8387}
}
EUVIMED